Grit GF, van Geffen E, Malmberg R, van Leeuwen R, et al. Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective. Lung Cancer 2024;196:107950.
PMID: 39236576